Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2018

Open Access 01-12-2018 | Research

Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis

Authors: Aoran Luo, Xiaoyan Jiang, Hong Ren

Published in: Virology Journal | Issue 1/2018

Login to get access

Abstract

Background

Currently, there is no consensus on the efficacy and safety of lamivudine (LAM) plus tenofovir disoproxil fumarate (TDF) combination therapy versus lamivudine monotherapy in HBV/HIV coinfected patients.

Methods

A comprehensive literature search was performed in English and Chinese databases. Both relevant dichotomous and continuous variables were extracted, and the combined outcomes were expressed as a risk ratio (RR) or a standard mean difference (SMD).

Results

Eleven eligible studies were included in our analysis. For HBV-relevant outcomes, the proportion of patients with undetectable HBV, the rates of serum alanine aminotransferase (ALT) normalization and hepatitis B e antigen (HBeAg) loss were higher in the combination therapy group than the monotherapy group (RR = 1.42, 95% CI: 1.14–1.76, P = 0.002; RR = 1.36, 95% CI: 1.17–1.58, P < 0.0001; RR = 2.74, 95% CI: 1.20–6.22, P = 0.02). In addition, the rate of HIV RNA-negative conversion was higher in the combination therapy group than the monotherapy group (RR = 1.26, 95% CI: 1.11–1.42, P = 0.0003).

Conclusion

LAM plus TDF combination therapy was more efficacious than LAM monotherapy in HBV/HIV coinfected patients. As time passes, this difference becomes more pronounced.
Appendix
Available only for authorised users
Literature
1.
Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44:6–9.CrossRef
2.
3.
Diederich WE, Steuber H. Therapy of viral infections. Topics Med Chem. 2015;2:35–56.
4.
Fischer J. Analogue-based drug discovery. Chemistry International -- Newsmagazine for IUPAC. 2010;32:12–5.
5.
Sharp M, Interpharma D, Sharp M, Interpharma D, Celle L, Cloud S. Sharp M. WHO Model List of Essential Medicines: Interpharma D; 2011.
6.
Brook G, Main J, Nelson M, Bhagani S, Wilkins E, Leen C, Fisher M, Gilleece Y, Gilson R, Freedman A. British HIV association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. Hiv Med. 2010;11:1–30.CrossRefPubMed
7.
Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, Sagnelli E, Coppola N. Hepatitis B virusburden in developing countries. World J Gastroentero. 2015;21:11941.CrossRef
8.
Stabinski L, Barnhart M, Kahn RJ, Hamm TE. Prevalence of HIV and hepatitis B virus co-infection in sub-Saharan Africa and the potential impact and program feasibility of hepatitis B surface antigen screening in resource-limited settings. J Acquir Immune Defic Syndr. 2015;3:274–85.CrossRef
9.
Price H, Dunn D, Pillay D, Banisadr F, Vriessluijs TD, Jain MK, Kuzushita N, Mauss S, Núñez M, Nüesch R. Suppression of HBV by Tenofovir in HBV/HIV Coinfected patients: a systematic review and meta-analysis. PLoS One. 2013;8:e68152.CrossRefPubMedPubMedCentral
10.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088.CrossRefPubMed
11.
Stuck AE, Rubenstein LZ, Wieland D, Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. 1998;316:469–77.
12.
Jain MK, Comanor L, White C, Kipnis P, Elkin C, Leung K, Ocampo A, Attar N, Keiser P, Lee WM. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J Viral Hepatitis. 2010;14:176–82.CrossRef
13.
Li Y, Xie J, Han Y, Wang H, Zhu T, Wang N, Lv W, Guo F, Qiu Z, Li Y, et al. Lamivudine monotherapy-based cART is efficacious for HBV treatment in HIV/HBV coinfection when baseline HBV DNA <20,000 IU/mL. J Acquir Immune Defic Syndr. 2016;72:39–45.CrossRefPubMedPubMedCentral
14.
Wang L, Wiener J, Bulterys M, Wei X, Chen L, Liu W, Liang S, Shepard C, Wang L, Wang A. Hepatitis B virus (HBV) load response to 2 antiviral regimens, Tenofovir/lamivudine and lamivudine, in HIV/ HBV-Coinfected pregnant women in Guangxi, China: the Tenofovir in pregnancy (TiP) study. J Infect Dis. 2016;214:1695.CrossRefPubMed
15.
Chen J-r. Clinical efficacy of tenofovir disoproxil combined with lamivudine in treating HIV with hepatitis B virus infected. Chin J of Clinical Rational Drug Use. 2017;10:21–2. [in Chinese]
16.
Chen R-f, Zheng Y-f, Xu S-f, Yang Q-e, Lu Y-h, Jiang Y-m. A 72-week on-treatment efficacy of de novo combination of tenofovir plus lamivudine based highly active antiretroviral therapy for HBV-HIV coinfected patients. Chinese Journal of Clinical Infectious Diseases. 2013;6:153–6. [in Chinese]
17.
Gao H-g. Tenofovir and Lamivudine in Treatment of AIDS Complicated with Hepatitis B Virus Infection. System Medicine. 2016;1:54–6. [in Chinese]
18.
He Z-y. The clinical efficacy and safety of hepatitis B virus infection patients combined with acquired immune deficiency syndrome treated by tenofovir disoproxil combined lamivudine. Chinese Journal of Experimental and Clinical Infectious Diseases: Electronic Edition. 2015;9:100–2. [in Chinese]
19.
Liu S-x. Observation of the efficacy of tenofovir combined with lamivudine in the treatment of AIDS with hepatitis B virus for 72 weeks. Modern Journal of Integrated Traditional Chinese and Western Medicine. 2017;26:992–4. [in Chinese]
20.
Luo J-f, Chen B, Yang S-x, Liu H-s, Hu Y-S, Lai Z-H, et al. Clinical observation of antiviral therapy against HIV infection with chronic hepatitis B virus infection. Contemporary Medicine. 2016;22:146–7. [in Chinese]
21.
Zhou M. Therapeutic effect and safety analysis of tenofovir dipivoxil combined with lamivudine and efavirenz on HIV/HBV coinfection. Med. Inf. 2016;29:50–1. [in Chinese]
22.
Zhou Y. Effect of tenofovir dipivoxil combined with lamivudine in the treatment of AIDS complicated with hepatitis B virus infection. Henan Medical Research. 2016;25:746–7. [in Chinese]
23.
Avihingsanon A, Lewin SS, Chang JJ, Piyawat K, Napissanant N, Matthews GV, Dore GJ, Bowden S, Lange J, Ruxrungtham K. Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand. Antivir Ther. 2010;15:917.CrossRefPubMed
24.
Garvey L, Curtis H, Brook G. The British HIV Association national audit on the management of subjects co-infected with HIV and hepatitis B/C. Int J STD AIDS. 2011;22:173–6.CrossRefPubMed
25.
Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resistance. J Hepatol. 2002;36:303–4.CrossRefPubMed
26.
Westland C, Delaney WT, Yang H, Chen SS, Marcellin P, Hadziyannis S, Gish R, Fry J, Brosgart C, Gibbs C, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology. 2003;125:107–16.CrossRefPubMed
27.
Guettouche T, Hnatyszyn HJ. Chronic hepatitis B and viral genotype: the clinical significance of determining HBV genotypes. Antivir Ther. 2005;10:593–604.PubMed
28.
Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36:687–96.CrossRefPubMed
29.
Yao GB, Zhu M, Cui ZY, Wang BE, Yao JL, Zeng MD. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis. 2009;10:131–7.CrossRefPubMed
30.
Gracey DM, Snelling P, Mckenzie P, Strasser SI. Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection. Antivir Ther. 2013;18:945.CrossRefPubMed
31.
Casado JL. Renal and bone toxicity with the use of Tenofovir: understanding at the end. AIDS Rev. 2016;18:59.PubMed
32.
Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRef
33.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2011;327:557–60.CrossRef
34.
Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 2010;7:889–94.CrossRef
35.
Wang SH, Chen PJ, Yeh SH. Gender disparity in chronic hepatitis B: mechanisms of sex hormones. Journal of Gastroenterology & Hepatology. 2015;30:1237.CrossRef
Metadata
Title
Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis
Authors
Aoran Luo
Xiaoyan Jiang
Hong Ren
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2018
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-018-1050-3

Other articles of this Issue 1/2018

Virology Journal 1/2018 Go to the issue

Research

Laboratory testing and phylogenetic analysis during a mumps outbreak in Ontario, Canada

Research

Emergence of HIV-1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana

Research

Ubiquitous giants: a plethora of giant viruses found in Brazil and Antarctica

Research

Inhibition of enterovirus 71 replication and viral 3C protease by quercetin

Research

Multiple organ involvement in severe fever with thrombocytopenia syndrome: an immunohistochemical finding in a fatal case

Research

Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits